EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial

Michael A Pfeffer, Tia C L Kohs, Helen H Vu, Kelley R Jordan, Jenny Si Han Wang iD, Christina U Lorentz iD, Erik I Tucker, Cristina Puy, Sven R Olson iD, Thomas G DeLoughery, Monica T Hinds iD, Ravi S Keshari und 4 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-01 · 44 (1) · 290-299

DOI: 10.1161/atvbaha.123.319692 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-01. Verfasst von Michael A Pfeffer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology (M.A.P., S.R.O., T.G.D., J.J.S.), Oregon Health & Science University, Portland. Hauptthemen laut MEDLINE: Thrombosis, Neoplasms. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors FXI (factor XI) and FXII (factor XII) represent novel targets for device-associated thrombosis, which may mitigate bleeding risk. Our objective was to evaluate the safety and efficacy of an anti-FXI mAb (monoclonal antibody), gruticibart (AB023), in a prospective, single-arm study of patients with cancer receiving central line placement. METHODS: We enrolled ambulatory cancer patients undergoing central line placement to receive a single dose of gruticibart (2 mg/kg) administered through the venous catheter within 24 hours of placement and a follow-up surveillance ultrasound at day 14 for evaluation of catheter thrombosis. A parallel, noninterventional study was used as a comparator. RESULTS: In total, 22 subjects (n=11 per study) were enrolled. The overall incidence of catheter-associated thrombosis was 12.5% in the interventional study and 40.0% in the control study. The anti-FXI mAb, gruticibart, significantly prolonged the activated partial thromboplastin time in all subjects on day 14 compared with baseline ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombosisNeoplasmsHumansFactor XIProspective StudiesHemorrhageCatheters

Stichwörter der Autor:innen

factor XIfollow-up studiesneoplasmsthromboembolismthrombosis

Substanzen

Factor XI

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology (M.A.P., S.R.O., T.G.D., J.J.S.), Oregon Health & Science University, Portland.
  • Department of Biomedical Engineering (T.C.L.K., H.H.V., K.R.J., J.S.H.W., C.U.L., E.I.T., C.P., M.T.H., O.J.T.M., J.J.S.), Oregon Health & Science University, Portland.
  • Aronora, Inc, Portland, OR (C.U.L., E.I.T.).
  • Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation (R.S.K., F.L.).
  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN (D.G.).

ORCID-Profile: Jenny Si Han Wang, Christina U Lorentz, Sven R Olson, Monica T Hinds, David Gailani

Förderung

  • NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Pfeffer, M. A., Kohs, T. C. L., Vu, H. H., Jordan, K. R., Wang, J. S. H., Lorentz, C. U., Tucker, E. I., Puy, C., Olson, S. R., DeLoughery, T. G., Hinds, M. T., Keshari, R. S., Gailani, D., Lupu, F., McCarty, O. J. T., & Shatzel, J. J. (2024). Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(1), 290-299. https://doi.org/10.1161/atvbaha.123.319692

Vancouver

Pfeffer MA, Kohs TCL, Vu HH, Jordan KR, Wang JSH, Lorentz CU, et al. Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(1):290-299. doi:10.1161/atvbaha.123.319692

BibTeX
@article{Pfeffer2024,
  author = {Pfeffer, Michael A and Kohs, Tia C L and Vu, Helen H and Jordan, Kelley R and Wang, Jenny Si Han and Lorentz, Christina U and Tucker, Erik I and Puy, Cristina and Olson, Sven R and DeLoughery, Thomas G and Hinds, Monica T and Keshari, Ravi S and Gailani, David and Lupu, Florea and McCarty, Owen J T and Shatzel, Joseph J},
  title = {Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  volume = {44},
  number = {1},
  pages = {290--299},
  doi = {10.1161/atvbaha.123.319692}
}
Kostenlos starten →